Theseus Pharmaceuticals, Inc.
THRXDelisted Feb 14, 2024- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001745020
Theseus Pharmaceuticals, Inc. was delisted on Feb 14, 2024; its insiders filed their last Form 4 on Feb 14, 2024; 70 institutions reported holding it in 13F filings for Q4 2023, worth $145.8M in total; no superinvestor held it.
Q3 2023 vs. Q2 2023
How the institutions holding Theseus Pharmaceuticals, Inc. changed between Q2 2023 and Q3 2023.
All holders in Q3 2023All holders in Q2 2023
| Measure | Q2 2023 | Of which not filed for Q3 2023 | Q3 2023 | Change |
|---|---|---|---|---|
| Holders | 69 | 1 | 63 | −5 |
| Shares | 40.0M | 75.0K | 35.3M | −4.67M (−11.7%) |
| Value | $373.6M | $699.8K | $95.5M | −$277.5M (−74.4%) |
1 institution that held it in Q2 2023 haven't filed for Q3 2023 yet. Not filing isn't selling, so the changes leave them out.
New holders (10)
Institutions that held Theseus Pharmaceuticals, Inc. at the end of Q3 2023 but not at the end of Q2 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Acadian Asset Management LLC | 259,470 | $696.0K | 0.00% |
| Gsa Capital Partners LLP | 36,587 | $98.0K | 0.01% |
| Walleye Capital LLC | 31,998 | $86.1K | 0.00% |
| Prelude Capital Management, LLC | 27,073 | $72.8K | 0.01% |
| Squarepoint Ops LLC | 19,653 | $52.9K | 0.00% |
| Forefront Analytics, LLC | 17,672 | $47.5K | 0.03% |
| Susquehanna International Group, LLP | 11,112 | $29.9K | 0.00% |
| American Century Companies Inc | 10,514 | $28.3K | 0.00% |
| Red Tortoise LLC | 536 | $1.44K | 0.00% |
| Glassman Wealth Services | 241 | $648 | 0.00% |
Sold out (15)
Institutions that held Theseus Pharmaceuticals, Inc. at the end of Q2 2023 and filed for Q3 2023 without it.
| Institution | Shares, Q2 2023 | Value, Q2 2023 |
|---|---|---|
| Paradigm Biocapital Advisors LP | 1,950,327 | $18.2M |
| Deerfield Management Company, L.P. (Series C) | 1,400,352 | $13.1M |
| VR Adviser, LLC | 770,000 | $7.18M |
| Janus Henderson Group PLC | 633,423 | $5.93M |
| Citadel Advisors LLC | 604,550 | $5.64M |
| Opaleye Management Inc. | 597,500 | $5.57M |
| Bank of Montreal | 277,074 | $2.80M |
| Candriam Luxembourg S.C.A. | 270,015 | $2.52M |
| Wellington Management Group LLP | 153,673 | $1.43M |
| HighVista Strategies LLC | 136,719 | $1.28M |
| Hudson Bay Capital Management LP | 35,000 | $326.6K |
| Goldman Sachs Group Inc | 28,941 | $270.0K |
| MetLife Investment Management | 10,330 | $96.4K |
| Metropolitan Life Insurance Co | 1,126 | $10.5K |
| Federated Hermes, Inc. | 163 | $1.52K |
Not filed for Q3 2023 yet (1)
Institutions that held Theseus Pharmaceuticals, Inc. at the end of Q2 2023 and haven't filed a 13F for Q3 2023. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q2 2023 | Value, Q2 2023 |
|---|---|---|
| Tekla Capital Management LLC | 75,000 | $699.8K |